Organization

City of Hope Medical Center

203 clinical trials

9 abstracts

Clinical trial

Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: An Adoptive Cellular Therapy for Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From Matched HLA Donors

Status: Not yet recruiting, Estimated PCD: 2026-12-12

Abstract

NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).

Org: Memorial Sloan Kettering Cancer Center, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Washington University School of Medicine in St. Louis, Washington University School of Medicine,

Abstract

The positive impact of Medicaid expansion on melanoma stage at presentation.

Org: City of Hope Comprehensive Cancer Center, City of Hope Medical Center, City of Hope National Comprehensive Cancer Center, City of Hope Cancer Center, City of Hope National Medical Center,

Clinical trial

A Phase 1/2 Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-11-23

Clinical trial

A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer

Status: Recruiting, Estimated PCD: 2025-04-30

Clinical trial

A Phase Ib Study of Durvalumab (Medi4736) and Tremelimumab Following Radioembolization in Patients With Unresectable Locally Advanced Hepatocellular Carcinoma

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units

Status: Active (not recruiting), Estimated PCD: 2009-11-11

Clinical trial

Phase I-II Study of Escalating Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy in Combination With Etoposide (VP16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients With Poor Risk Acute Lymphocytic Leukemia (ALL) or Poor Risk Acute Myelogenous Leukemia (AML)

Status: Active (not recruiting), Estimated PCD: 2016-05-30

Clinical trial

Pilot Study: Detection of Colorectal Metastatic Liver Disease Preoperatively Using 124I-Labeled M5A Monoclonal Antibody to Carcinoembryonic Antigen (CEA)

Status: Active (not recruiting), Estimated PCD: 2024-06-08

Clinical trial

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin

Status: Active (not recruiting), Estimated PCD: 2024-12-22

Clinical trial

A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma

Status: Recruiting, Estimated PCD: 2024-09-01

Clinical trial

Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy

Status: Active (not recruiting), Estimated PCD: 2017-02-14

Clinical trial

A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma

Status: Recruiting, Estimated PCD: 2025-06-01

Clinical trial

Phase II Study of Talazoparib With Androgen Deprivation Therapy and Abiraterone in Castration Sensitive Prostate Cancer

Status: Recruiting, Estimated PCD: 2027-08-23

Clinical trial

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination With Endocrine Therapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

Status: Recruiting, Estimated PCD: 2024-08-21

Clinical trial

Pre-Surgical EPS Biomarkers as Predictors of Biochemical Recurrence

Status: Active (not recruiting), Estimated PCD: 2016-07-13

Clinical trial

Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)

Status: Active (not recruiting), Estimated PCD: 2022-03-06

Clinical trial

A Phase 1b Trial of the IRX-2 Regimen and Nivolumab in Patients With Advanced Hepatocellular Cancer (HCC)

Status: Active (not recruiting), Estimated PCD: 2024-12-15

Clinical trial

Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma

Status: Active (not recruiting), Estimated PCD: 2024-06-14

Clinical trial

A First-in-Human Study to Evaluate the Safety, Feasibility and Tolerability of Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Status: Recruiting, Estimated PCD: 2028-05-21

Clinical trial

A Phase I/II Study of VELCADE in Combination With Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma

Status: Completed, Estimated PCD: 2016-08-25

Clinical trial

A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2024-06-30

Clinical trial

Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms

Status: Active (not recruiting), Estimated PCD: 2024-12-30

Clinical trial

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan

Status: Completed, Estimated PCD: 2019-05-30

Clinical trial

A Phase 2 Study of Mosunetuzumab With Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

Status: Not yet recruiting, Estimated PCD: 2027-03-18

Clinical trial

MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2022-04-01

Clinical trial

Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors

Status: Active (not recruiting), Estimated PCD: 2013-01-19

Clinical trial

Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission

Status: Active (not recruiting), Estimated PCD: 2019-12-27

Clinical trial

Whole Body MRI and Liquid Biopsy for Early Cancer Detection

Status: Active (not recruiting), Estimated PCD: 2024-07-20

Clinical trial

A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-03-31

Clinical trial

A Phase Ib Open Label Study of Navitoclax in Combination With Venetoclax + Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Status: Active (not recruiting), Estimated PCD: 2024-07-29

Clinical trial

Phase 2a Study of Adding Ruxolitinib With Tacrolimus/Methotrexate Regimen for Graft-versus-Host Disease Prophylaxis in Myeloablative Conditioning Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients

Status: Not yet recruiting, Estimated PCD: 2027-10-31

Clinical trial

A Feasibility Study of Bridging Radiation to All Sites of FDG-Avid Disease for Commercial CAR T-Cell Infusion in Patients With Large B-Cell Lymphoma

Status: Recruiting, Estimated PCD: 2024-10-20

Clinical trial

Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia

Status: Recruiting, Estimated PCD: 2025-08-04

Clinical trial

Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Status: Completed, Estimated PCD: 2018-09-18

Clinical trial

A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer

Status: Completed, Estimated PCD: 2023-07-14

Clinical trial

Phase I Study of Yttrium-90 Labeled Anti-CD25 (a-Tac) Monoclonal Antibody Plus BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma, the "a-Tac BEAM Regimen"

Status: Active (not recruiting), Estimated PCD: 2021-07-24

Clinical trial

A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)

Status: Completed, Estimated PCD: 2024-02-09

Clinical trial

Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors

Status: Recruiting, Estimated PCD: 2024-08-24

Clinical trial

A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer

Status: Active (not recruiting), Estimated PCD: 2020-10-04

Clinical trial

A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2026-03-19

Clinical trial

Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients With Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study.

Status: Active (not recruiting), Estimated PCD: 2025-09-03

Abstract

Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.

Org: UT Southwestern Medical Center, Dallas, City of Hope National Comprehensive Cancer Center, Duarte, CA, Memorial Sloan Kettering Cancer Center,

Clinical trial

Pilot Trial of Leflunomide in Patients With High-Risk Smoldering Multiple Myeloma

Status: Active (not recruiting), Estimated PCD: 2024-12-30

Clinical trial

Pilot Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation

Status: Active (not recruiting), Estimated PCD: 2024-12-15

Clinical trial

A Phase 2 Study of Glofitamab With Acalabrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Status: Recruiting, Estimated PCD: 2026-09-30

Clinical trial

Biomarkers, Breast Density And Risk Reduction Perspectives In BRCA Carriers

Status: Active (not recruiting), Estimated PCD: 2024-06-15

Clinical trial

A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL

Status: Recruiting, Estimated PCD: 2025-05-16

Clinical trial

A Phase II Trial of Stereotactic Body Radiation Therapy and Fluoroestradiol Positron Emission Tomography in Patients With Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2025-12-11

Clinical trial

A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological Malignancies

Status: Active (not recruiting), Estimated PCD: 2026-05-05

Clinical trial

An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors

Status: Completed, Estimated PCD: 2017-08-04

Clinical trial

64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2018-10-23

Clinical trial

Phase IIa Study of Addition of Itacitinib With Tacrolimus/Sirolimus Regimen for GVHD Prophylaxis in Fludarabine and Melphalan Non-Myeloablative Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, MDS or MF

Status: Active (not recruiting), Estimated PCD: 2023-05-22

Clinical trial

Phase 1b Study of IDH Inhibition With Enasidenib and MEK Inhibition With Cobimetinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Status: Recruiting, Estimated PCD: 2025-05-02

Clinical trial

A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2021-01-30

Clinical trial

Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma

Status: Completed, Estimated PCD: 2016-05-18

Clinical trial

A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2023-06-23

Clinical trial

A Phase 2 Study With a Safety Lead-In of the Anti-CD19 Antibody Tafasitamab With the BTK Inhibitor Zanubrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) - TaZa CLL Study

Status: Recruiting, Estimated PCD: 2025-10-19

Clinical trial

Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Status: Recruiting, Estimated PCD: 2028-11-11

Clinical trial

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Status: Not yet recruiting, Estimated PCD: 2027-02-24

Clinical trial

A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas

Status: Completed, Estimated PCD: 2021-04-21

Clinical trial

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2025-04-09

Clinical trial

A Phase II Study of Intermittent Duvelisib Dosing in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Status: Active (not recruiting), Estimated PCD: 2024-06-27

Clinical trial

A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-06-22

Clinical trial

A Phase 1 Trial of 8-Chloro-Adenosine in Combination With Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status: Recruiting, Estimated PCD: 2027-01-25

Clinical trial

Phase 1/2 Study of the Combination of Glofitamab, Venetoclax and Lenalidomide in Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Status: Recruiting, Estimated PCD: 2024-12-28

Clinical trial

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without Stem Cell Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2024-10-02

Clinical trial

Multi-Modality Imaging and Correlative Studies in Patients With Leukemia

Status: Recruiting, Estimated PCD: 2024-11-06

Clinical trial

Status: Active (not recruiting), Estimated PCD: 2024-09-24

Clinical trial

A Randomized Open Label Pilot Study of Clostridium Butyricum MIYAIRI 588 (CBM588) in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Status: Active (not recruiting), Estimated PCD: 2024-12-24

Clinical trial

Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

Status: Active (not recruiting), Estimated PCD: 2024-12-30

Clinical trial

A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas

Status: Recruiting, Estimated PCD: 2025-08-07

Clinical trial

A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)

Status: Active (not recruiting), Estimated PCD: 2025-01-30

Clinical trial

Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen

Status: Active (not recruiting), Estimated PCD: 2020-09-18

Clinical trial

Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients </=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as the Preparative Regimen

Status: Active (not recruiting), Estimated PCD: 2022-12-31

Clinical trial

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Cabozantinib/Nivolumab for Patients With Metastatic Renal Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-10-25

Clinical trial

Phase 2 Trial of Leflunomide in African-American and European-American Patients With High-Risk Smoldering Multiple Myeloma

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2021-03-03

Clinical trial

Improving Islet Transplantation Outcomes With Gastrin

Status: Recruiting, Estimated PCD: 2026-02-01

Clinical trial

Combination Nivolumab and Ipilimumab With and Without Camu Camu in First Line Treatment of Metastatic Renal Cell Carcinoma

Status: Recruiting, Estimated PCD: 2026-03-14

Clinical trial

A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis

Status: Recruiting, Estimated PCD: 2025-03-24

Clinical trial

A Multi-Center, Phase 1 Trial of Combining Anti-CD47 Antibody (Magrolimab) With Azacitidine as Post-Transplant Maintenance Therapy in Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation for Treatment of High-Risk AML or MDS

Status: , Estimated PCD: 2025-05-03

Clinical trial

Phase II Trial of Extracorporeal Photopheresis (ECP) Plus Low Dose IL-2 for Treatment of Steroid Refractory Chronic Graft-versus-Host Disease (cGVHD)

Status: Completed, Estimated PCD: 2018-10-16

Clinical trial

Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status: Recruiting, Estimated PCD: 2025-11-04

Clinical trial

A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia

Status: Active (not recruiting), Estimated PCD: 2024-12-15

Clinical trial

Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors

Status: Active (not recruiting), Estimated PCD: 2025-09-30

Clinical trial

A Phase II Study of Cabozantinib and Temozolomide in Patients With Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia

Status: Completed, Estimated PCD: 2021-03-09

Clinical trial

High Dose Chemotherapy and Combination Anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma

Status: Active (not recruiting), Estimated PCD: 2024-12-30

Clinical trial

A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimeric Oncolytic Poxvirus Encoding Human Sodium Iodide Symporter (HNIS) in Patients With Metastatic Triple Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-09-22

Clinical trial

A Pilot Study of Pre-transplant Immunosuppressive Therapy for Haploidentical Transplants in Patients With Sickle Cell Disease

Status: Recruiting, Estimated PCD: 2025-03-19

Clinical trial

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Status: Active (not recruiting), Estimated PCD: 2024-09-23

Clinical trial

Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies

Status: Active (not recruiting), Estimated PCD: 2013-08-01

Clinical trial

Phase 2 Study of Bright White Light During Treatment With ADT Combination Therapy in Men With Advanced Prostate Cancer to PreServe PHysIcal and MeNtal HEalth (SHINE)

Status: Recruiting, Estimated PCD: 2027-12-01

Clinical trial

Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Status: Active (not recruiting), Estimated PCD: 2013-10-03

Clinical trial

Randomized Observer-Blinded Phase 2 Trial of COVID-19 Booster With GEO-CM04S1 or mRNA Vaccine in Patients With Chronic Lymphocytic Leukemia

Status: Recruiting, Estimated PCD: 2026-01-12

Clinical trial

Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia

Status: Active (not recruiting), Estimated PCD: 2024-06-15

Clinical trial

Single Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning Matched Donor Hematopoietic Cell Transplantation With Peripheral Blood Stem Cells as Graft Source

Status: Recruiting, Estimated PCD: 2024-04-28

Clinical trial

Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Advanced Myeloid Malignancies

Status: Terminated, Estimated PCD: 2011-05-17

Clinical trial

Pilot Study of Total Marrow/Lymphoid Irradiation (TMLI) Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplant (HCT) Followed by Post Transplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis for Acute Myelogenous Leukemia in Complete Remission

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC)

Status: Recruiting, Estimated PCD: 2025-12-30

Clinical trial

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Status: Active (not recruiting), Estimated PCD: 2024-12-15

Clinical trial

Pilot Trial Using 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy for Oligo-Progressive Solid Tumors

Status: Withdrawn, Estimated PCD: 2026-11-08

Clinical trial

Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Status: Recruiting, Estimated PCD: 2024-12-13

Clinical trial

Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2017-05-17

Clinical trial

A Phase Ib Open-Label Study of LB-100 in Combination With Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage Small Cell Lung Carcinoma

Status: Recruiting, Estimated PCD: 2026-03-09

Clinical trial

A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease

Status: Recruiting, Estimated PCD: 2024-09-06

Clinical trial

A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders

Status: Active (not recruiting), Estimated PCD: 2007-03-13

Clinical trial

Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2011-03-16

Clinical trial

Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant

Status: Active (not recruiting), Estimated PCD: 2024-11-17

Clinical trial

A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Status: Recruiting, Estimated PCD: 2024-06-30

Clinical trial

A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of CMV-MVA Triplex Vaccine in Adult Recipients of Haploidentical Hematopoietic Stem Cell Transplant

Status: Active (not recruiting), Estimated PCD: 2030-04-07

Clinical trial

Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect

Status: Completed, Estimated PCD: 2022-01-20

Clinical trial

A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas

Status: Active (not recruiting), Estimated PCD: 2022-02-21

Clinical trial

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

Status: Active (not recruiting), Estimated PCD: 2024-11-27

Clinical trial

Pilot Study: Imaging Tumor Extent and Response Before and After Neoadjuvant Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)

Status: Recruiting, Estimated PCD: 2025-11-12

Clinical trial

A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Status: Completed, Estimated PCD: 2024-02-02

Clinical trial

Phase I Study of Ursodeoxycholic Acid (Ursodiol)in Combination With 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Cancer

Status: Active (not recruiting), Estimated PCD: 2012-09-25

Clinical trial

A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma

Status: Completed, Estimated PCD: 2022-05-24

Clinical trial

Status: Active (not recruiting), Estimated PCD: 2011-10-25

Clinical trial

A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine

Status: Active (not recruiting), Estimated PCD: 2021-12-07

Clinical trial

A Phase 1 Study of Gemcitabine, Nab-Paclitaxel, and Bosentan in Patients With Unresectable Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2026-01-27

Clinical trial

Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Metastatic Renal Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-06-11

Clinical trial

Phase 1 Trial of 111Indium/225Actinium-DOTA-Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma

Status: Recruiting, Estimated PCD: 2025-03-22

Clinical trial

A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

Status: Active (not recruiting), Estimated PCD: 2023-05-03

Clinical trial

Islet Transplantation Using a T-Cell Depleting Immunosuppression Induction Regimen

Status: Active (not recruiting), Estimated PCD: 2025-10-16

Clinical trial

Phase I Trial of Radiotherapy in Combination With Atezolizumab in Borderline Resectable and Unresectable Cutaneous Squamous Cell Carcinoma(cSCC)

Status: Recruiting, Estimated PCD: 2024-12-01

Clinical trial

Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)

Status: Recruiting, Estimated PCD: 2028-03-30

Clinical trial

Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies

Status: Active (not recruiting), Estimated PCD: 2010-04-12

Clinical trial

A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

Status: Not yet recruiting, Estimated PCD: 2025-10-31

Clinical trial

A Pilot / Feasibility Study of Autologous CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine in Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2028-03-30

Clinical trial

A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas

Status: Active (not recruiting), Estimated PCD: 2027-04-25

Clinical trial

Pilot Trial of Leflunomide in Patients With CD30+ Lymphoproliferative Disorders

Status: Completed, Estimated PCD: 2021-07-28

Clinical trial

A Phase II Study of BTK Inhibitor Acalabrutinib and PI3Kδ Inhibitor Umbralisib in Combination With Ublituximab (AU2) in Patients With Previously Untreated Mantle Cell Lymphoma (MCL)

Status: Active (not recruiting), Estimated PCD: 2022-07-31

Clinical trial

A Single Center, Non-Randomized, Phase 1b Study of Orca-T Following Escalated Dose of Total Marrow and Lymphoid Irradiation in Patients With Acute Leukemias and MDS

Status: Recruiting, Estimated PCD: 2027-06-21

Clinical trial

CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant

Status: Active (not recruiting), Estimated PCD: 2022-01-22

Clinical trial

Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma

Status: Active (not recruiting), Estimated PCD: 2010-02-09

Clinical trial

Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2013-12-30

Clinical trial

Pilot Open-Label Study of Safety and Efficacy of Ruxolitinib Given Peri-Transplant During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelofibrosis

Status: Completed, Estimated PCD: 2020-04-16

Clinical trial

A Randomized Phase 2 Trial of White Button Mushroom Supplement in Patients With Biochemically Recurrent Prostate Cancer Following Local Therapy and in Therapy Na?ve Patients With Favorable Risk Prostate Cancer Undergoing Active Surveillance

Status: Recruiting, Estimated PCD: 2024-04-30

Clinical trial

A Phase 1 Study to Evaluate Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Primary CNS Lymphoma

Status: Recruiting, Estimated PCD: 2026-07-29

Clinical trial

A Phase I Study of Actinium-225 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced or Metastatic Cancers

Status: Recruiting, Estimated PCD: 2025-08-07

Clinical trial

Phase I/II Trial of Niraparib/Selenium Combination Treatment in Patients With BRCA1/2-Wild Type Recurrent Platinum-Resistant Ovarian Cancer

Status: Not yet recruiting, Estimated PCD: 2026-11-27

Clinical trial

A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

Status: Active (not recruiting), Estimated PCD: 2018-03-04

Clinical trial

Phase II Trial of Lung Chemoembolization

Status: Recruiting, Estimated PCD: 2024-10-31

Clinical trial

A Phase 2 Study to Evaluate CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells Combined With Acalabrutinib for Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Status: Recruiting, Estimated PCD: 2024-09-02

Clinical trial

A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation

Status: Completed, Estimated PCD: 2020-11-02

Clinical trial

A Pilot Study to Evaluate the Feasibility and Safety of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV-HIV CAR) T Cells in People Living With HIV

Status: Not yet recruiting, Estimated PCD: 2026-03-30

Clinical trial

A Phase I De-Escalation Study of Dexamethasone With Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma

Status: Not yet recruiting, Estimated PCD: 2024-11-29

Clinical trial

A Pilot Study to Evaluate the Safety and Feasibility of Autologous Tolerogenic Dendritic Cells Loaded With Proinsulin Peptide (C19-A3) in Patients With Type 1 Diabetes

Status: Recruiting, Estimated PCD: 2024-10-10

Clinical trial

A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia

Status: Recruiting, Estimated PCD: 2024-05-22

Clinical trial

A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant

Status: Recruiting, Estimated PCD: 2024-11-11

Clinical trial

A Phase 1 Study of Mezigdomide (CC-92480) and Dexamethasone Post Idecabtagene Vicleucel in Relapsed Multiple Myeloma

Status: Recruiting, Estimated PCD: 2026-03-21

Clinical trial

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2018-02-22

Clinical trial

A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2021-09-29

Clinical trial

A Randomized Clinical Trial Comparing Supplemental Topical Treatments for Acute Radiation Dermatitis in Breast Cancer Patients

Status: Recruiting, Estimated PCD: 2024-06-21

Clinical trial

Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma

Status: Active (not recruiting), Estimated PCD: 2023-12-18

Clinical trial

Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2019-01-11

Clinical trial

A Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Status: Completed, Estimated PCD: 2011-01-01

Clinical trial

High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2023-03-21

Clinical trial

Pilot Trial of Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2025-07-05

Clinical trial

Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer

Status: Completed, Estimated PCD: 2020-03-12

Clinical trial

A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer

Status: Completed, Estimated PCD: 2022-12-09

Clinical trial

Randomized Pilot Trial of Oral Cyclophosphamide Versus Oral Cyclophosphamide With Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: Completed, Estimated PCD: 2011-04-21

Clinical trial

A Phase 1/2 Study of Tazemetostat With Umbralisib and Ublituximab in Patients With Relapsed/Refractory Follicular Lymphoma

Status: Withdrawn, Estimated PCD: 2024-12-15

Clinical trial

A Pilot Study of CD19-Specific Car T Cells as Consolidation for Older Adults With Acute Lymphoblastic Leukemia in First Remission

Status: Recruiting, Estimated PCD: 2026-07-24

Clinical trial

A Phase I/II Trial of Botensilimab, Balstilimab and Regorafenib (BBR) in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Who Progressed on Prior Chemotherapy

Status: Recruiting, Estimated PCD: 2024-11-09

Clinical trial

A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients

Status: Active (not recruiting), Estimated PCD: 2020-09-20

Clinical trial

Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2021-01-12

Clinical trial

A Pilot Study of Nonmyeloablative Regimen Using Total Marrow and Lymphoid Irradiation for Irradiation Sparing of Bystander Organs in Hematopoietic Cell Transplantation From Matched Related or Unrelated Donor in Patients With Sickle Cell Disease

Status: Recruiting, Estimated PCD: 2028-10-26

Clinical trial

A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia

Status: Active (not recruiting), Estimated PCD: 2023-04-01

Clinical trial

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer

Status: Recruiting, Estimated PCD: 2026-04-05

Clinical trial

Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma

Status: Active (not recruiting), Estimated PCD: 2019-07-20

Clinical trial

Intra-operative Optical Imaging Utilizing Anti-PSMA (Prostate Specific Membrane Antigen) Fluorescent Antibody During Robotic Assisted Laparoscopic Prostatectomy

Status: Completed, Estimated PCD: 2018-05-10

Clinical trial

A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Patients With Metastatic Triple Negative Breast Cancer

Status: Completed, Estimated PCD: 2023-01-21

Clinical trial

Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzum-Based Neoadjuvant Therapy

Status: Active (not recruiting), Estimated PCD: 2020-07-02

Clinical trial

A Phase 2 Trial of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy (aTac-BEAM) Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2027-10-02

Clinical trial

A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant

Status: Active (not recruiting), Estimated PCD: 2018-01-25

Clinical trial

Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases

Status: Recruiting, Estimated PCD: 2028-10-11

Clinical trial

A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

Status: Terminated, Estimated PCD: 2023-06-18

Clinical trial

A Randomized, Phase II Study Assessing Axitinib as Pre-Surgical Therapy in Patients With High Risk Prostate Cancer

Status: Completed, Estimated PCD: 2013-10-09

Clinical trial

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Status: Active (not recruiting), Estimated PCD: 2024-08-30

Clinical trial

A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)

Status: Completed, Estimated PCD: 2020-10-28

Clinical trial

A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma

Status: Recruiting, Estimated PCD: 2024-07-31

Clinical trial

A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Status: Recruiting, Estimated PCD: 2024-10-30

Clinical trial

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas

Status: Active (not recruiting), Estimated PCD: 2021-07-16

Clinical trial

A Phase I Study of Intratumoral Injections of CpG-STAT3 siRNA (CAS3/SS3) in Combination With Local Radiation in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL)

Status: Withdrawn, Estimated PCD: 2024-01-04

Clinical trial

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-09-28

Clinical trial

Phase Ib Study to Evaluate Humanized CD19-Specific CAR T Cells Following Lymphodepleting Chemotherapy in Adult Patients With Relapsed/Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia

Status: Recruiting, Estimated PCD: 2025-08-06

Clinical trial

A Phase 1b Study Evaluating Combinations With PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting, Estimated PCD: 2027-08-01

Clinical trial

Placebo-Controlled and Randomized Phase 2 Trial of CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients After Hematopoietic Stem Cell Transplant

Status: Recruiting, Estimated PCD: 2027-01-01

Clinical trial

A Pilot/Feasibility Trial of 64Cu-DOTA-Daratumumab Positron Emission Tomography in Patients With Newly Diagnosed or Relapsed Multiple Myeloma

Status: Completed, Estimated PCD: 2020-01-22

Clinical trial

A Phase II Trial of Cemiplimab Alone for Untreated Brain Metastases From PD-L1 ≥ 50% Non-Small Cell Lung Cancer

Status: Recruiting, Estimated PCD: 2028-01-02

Clinical trial

Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer

Status: Recruiting, Estimated PCD: 2024-12-30

Clinical trial

A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Severe Aplastic Anemia Patients With COH-MC-17: A Non-Myeloablative/ Reduced-Intensity, Conditioning Regimen and CD4+ T-Cell-Depleted Haploidentical Hematopoietic Transplant

Status: Recruiting, Estimated PCD: 2026-10-26

Clinical trial

A Phase 2 Study of Epcoritamab and Lenalidomide (E-Len) in Patients With Previously Untreated Follicular Lymphoma (FL)

Status: Recruiting, Estimated PCD: 2025-10-14

Abstract

Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma.

Org: Chimeric Therapeutics, St.David's South Austin Medical Center, City of Hope Medical Center,

Abstract

AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.

Org: H. Lee Moffitt Cancer Center and Research Institute, Onc.AI, Ohio State University Comprehensive Canvcer Hospital, University of Rochester Medical Center Department of Neurobiology and Anatomy, Earle A Chiles Research Institute,

Abstract

Patient-reported hope, prognostic understanding, quality of life, symptom burden, coping mechanisms, and financial wellbeing in early phase clinical trial participants.

Org: Massachusetts General Hospital, Brigham & Women's Hospital, Division of Palliative Care and Geriatric Medicine, Florida State University, City of Hope Medical Center,

Abstract

Financial toxicity, quality of life, symptom burden, and access to resources in early-phase clinical trial (EP-CT) participants.

Org: Massachusetts General Hospital, Brigham & Women's Hospital, Division of Palliative Care and Geriatric Medicine, Florida State University, City of Hope Medical Center,

Abstract

The association of sociodemographic variables with smoking prevalence in patients enrolled on clinical trials.

Org: City of Hope National Comprehensive Cancer Center, Duarte, CA, CanSino Biologics, SWOG Statistics and Data Management Center, Seattle, WA, Seattle Gummy Company,

Abstract

Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.

Org: Onc.AI, University of Rochester Medical Center Department of Neurobiology and Anatomy, Ohio State University Comprehensive Canvcer Hospital, City of Hope Medical Center, City of Hope National Medical Center,

Clinical trial

A Phase 2 Study of Glofitamab With Acalabrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Status: Recruiting, Estimated PCD: 2026-10-16

Clinical trial

Phase 2 Study of Bright White Light During Treatment With ADT Combination Therapy in Men With Advanced Prostate Cancer to PreServe PHysIcal and MeNtal HEalth (SHINE)

Status: Recruiting, Estimated PCD: 2027-12-01

Clinical trial

A Phase 1b Study of the Multi-Kinase Inhibitor Regorafenib in Combination With the BCL-2 Inhibitor Venetoclax Plus Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Status: Not yet recruiting, Estimated PCD: 2027-02-17

Clinical trial

A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2026-11-13